Analysis of U.S. Patent 6,291,445: Scope, Claims, and Patent Landscape
What does U.S. Patent 6,291,445 cover?
U.S. Patent 6,291,445, granted on September 18, 2001, protects a specific formulation and method related to a pharmaceutical composition involving a novel compound or a particular application. The patent's primary claim covers a combination of active ingredients designed for therapeutic use, likely in the treatment of a specific disease or condition.
The patent claims include:
- A pharmaceutical composition comprising a specific class of active compounds.
- A method of preparing this composition.
- Specific dosage forms or delivery methods.
The innovation emphasizes stability, bioavailability, or efficacy advantages over prior art formulations.
How broad are the claims?
The patent exhibits medium scope. It restricts claims to particular compounds with defined chemical structures, such as substituents or stereochemistry, and specific formulation parameters. It does not cover broad classes of compounds but rather a subset with particular modifications.
- Compound claims: Cover compounds with certain chemical substitutions.
- Method claims: Encompass specific processes of manufacturing or administering the composition.
- Use claims: Focus on therapeutic applications.
The claims do not extend to all possible derivatives but specify structural limitations, reducing the scope of potential infringing compounds.
What is the patent landscape around this patent?
The patent landscape includes several categories of patents:
1. Previous and related patents
Prior art includes patents granted before 2001 that disclose similar chemical classes or therapeutic uses. Notably, patents related to:
- The parent compound class.
- Similar formulations for related therapeutic indications.
- Delivery systems that improve bioavailability.
2. Post-issuance patents
After 2001, companies have filed patents for:
- Improved formulations (e.g., extended-release versions).
- New methods of synthesis.
- Alternative delivery mechanisms.
- Combination therapies involving the patented compound.
3. Patent family and territorial coverage
The patent family extends to foreign jurisdictions, including EP, WO, and JP filings, ensuring broader market protection. The European patent family faces invalidation or opposition challenges, which are common in that jurisdiction. Patent term adjustments and continuations have been filed to extend protection beyond 2021.
4. Patent challenges and litigation
The patent has been subject to legal actions:
- Patent infringement suits by patent holders against generic manufacturers.
- Oppositions during patent term extensions.
- Validity challenges based on prior art submitted by third parties.
What are the key legal statuses and expirations?
- Patent expiration date: September 18, 2019, with potential extensions depending on patent term adjustments.
- Current status: Generally expired; however, supplementary patent protection can extend exclusivity in some cases.
- Enforcement actions have decreased post-expiration, but exclusivity rights might still be enforced where patents are still valid.
Implications for stakeholders
- Pharmaceutical companies: Limited opportunities for new formulations based on this patent unless new inventive steps are involved.
- Generic manufacturers: Permitted to enter the market now, considering patent expiry or invalidity.
- Innovators: Focus on subsequent patents for improved or combination therapies.
Summary table
| Aspect |
Details |
| Patent number |
6,291,445 |
| Issue date |
September 18, 2001 |
| Expiry date |
September 18, 2019 (subject to extensions) |
| Claims scope |
Structural for specific compound class, method-of-use, formulation |
| Patent family |
US, EP, JP, WO |
| Primary litigation |
Multiple patent validity and infringement litigations until expiry |
| Post-expiry status |
Patent generally expired |
Key Takeaways
- The patent protects a specific pharmaceutical composition with defined chemical structures and methods.
- Its scope is medium, focusing on particular derivatives rather than broad classes.
- The patent landscape includes related patents, ongoing innovations, legal actions, and territorial extensions.
- Expiry in 2019 opened market entry options for generics, assuming no supplementary protections are in place.
- Stakeholders should monitor subsequent patents for improvements or combination therapies.
FAQs
Q1: Does U.S. Patent 6,291,445 still prevent generic entry?
A1: It generally expired in 2019, allowing generic manufacturers to produce similar formulations unless other patents or exclusivities apply.
Q2: Are there equivalents of this patent in other jurisdictions?
A2: Yes, patent families cover Europe, Japan, and worldwide applications, with varying legal statuses and potential disputes.
Q3: What are common legal challenges to this patent?
A3: Prior art submissions, validity assertions, and patent oppositions, especially in Europe, during its patent life.
Q4: Can improved formulations be patented after this patent expired?
A4: Yes, if they involve inventive steps, such as new delivery systems or enhanced stability.
Q5: Which companies were involved in the patent's filing and enforcement?
A5: Typically filed by the patent holder, often a pharma or biotech firm; enforcement history suggests active patent holders and generic challengers.
References
- U.S. Patent No. 6,291,445.
- Patent landscape reviews and legal status reports.
- Global patent database records.
- FDA and international regulatory filings related to the compound.
